CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in ...

After Bicara reported a 12-month OS of 61% for its HPV-negative population last week, biotech Merus shared that its ...

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with ...

Drugs that boost the body's immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell ...

Classification of immune profiling on tumor samples helps explain improving treatment outcomes, paving the way for ...

The envisioned flow cytometry test will help to predict patient response to immunotherapies for five cancer indications.

Ty Labbe, a retired homicide detective from the Los Angeles County Sheriff’s Department, faced one of the toughest battles of ...

Human papillomavirus (HPV) whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) detection has the highest ...